TY - JOUR
T1 - Clinical Phage Microbiology
T2 - a suggested framework and recommendations for the in-vitro matching steps of phage therapy
AU - Gelman, Daniel
AU - Yerushalmy, Ortal
AU - Alkalay-Oren, Sivan
AU - Rakov, Chani
AU - Ben-Porat, Shira
AU - Khalifa, Leron
AU - Adler, Karen
AU - Abdalrhman, Mohanad
AU - Coppenhagen-Glazer, Shunit
AU - Aslam, Saima
AU - Schooley, Robert T.
AU - Nir-Paz, Ran
AU - Hazan, Ronen
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
PY - 2021/10
Y1 - 2021/10
N2 - Phage therapy is a promising solution for bacterial infections that are not eradicated by conventional antibiotics. A crucial element of this approach is appropriate matching of bacteriophages and antibiotics to the bacterial target according to the clinical setting. However, there is currently little consistency in the protocols used for the laboratory evaluation of bacteriophages intended for antibacterial treatment. In this Personal View, we suggest a framework aimed to match appropriate bacteriophage-based treatments in clinical microbiology laboratories. This framework, which we have termed Clinical Phage Microbiology, is based on the current research on phage treatments. In addition, we discuss special cases that might require additional relevant evaluation, including bacteriophage interactions with the host immune response, biofilm-associated infections, and polymicrobial infections. The Clinical Phage Microbiology pipeline could serve as the basis for future standardisation of laboratory protocols for personalised phage therapy.
AB - Phage therapy is a promising solution for bacterial infections that are not eradicated by conventional antibiotics. A crucial element of this approach is appropriate matching of bacteriophages and antibiotics to the bacterial target according to the clinical setting. However, there is currently little consistency in the protocols used for the laboratory evaluation of bacteriophages intended for antibacterial treatment. In this Personal View, we suggest a framework aimed to match appropriate bacteriophage-based treatments in clinical microbiology laboratories. This framework, which we have termed Clinical Phage Microbiology, is based on the current research on phage treatments. In addition, we discuss special cases that might require additional relevant evaluation, including bacteriophage interactions with the host immune response, biofilm-associated infections, and polymicrobial infections. The Clinical Phage Microbiology pipeline could serve as the basis for future standardisation of laboratory protocols for personalised phage therapy.
UR - http://www.scopus.com/inward/record.url?scp=85129900775&partnerID=8YFLogxK
U2 - 10.1016/S2666-5247(21)00127-0
DO - 10.1016/S2666-5247(21)00127-0
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:85129900775
SN - 2666-5247
VL - 2
SP - e555-e563
JO - The Lancet Microbe
JF - The Lancet Microbe
IS - 10
ER -